New Delhi, Sept. 7 -- Hyderabad-based drugmaker HRV Pharma is expanding its peptides and oncology capabilities through manufacturing partnerships, seeking to tap niche and complex segments while keeping its business asset-light, a senior executive told Mint.

The pharmaceutical platform, which owns the intellectual property (IP) and regulatory rights to its products while outsourcing manufacturing and commercialization to partners, is investing about Rs.150 crore in dedicated capacity for the two segments.

The firm has signed an agreement with Hyderabad-based Arene Lifesciences to jointly invest Rs.50 crore in a dedicated peptide facility, on commercial-stage and new-to-generic synthetic peptides across multiple therapeutic areas, with H...